The protein drug developer has now secured more than $195m in total, its earlier backers including GlaxoSmithKline, Pfizer, Eli Lilly and Schrödinger.

Nimbus Therapeutics, the US-based small molecule drug developer backed by life sciences software provider Schrödinger and pharmaceutical firms Pfizer, GlaxoSmithKline and Eli Lilly, completed a $60m financing round yesterday.

Investment management firm RA Capital Management and investment partnership BVF Partners provided the capital, which took the company’s total funding to more than $195m.

Founded in 2009, Nimbus has built a drug discovery platform that is used to create small molecule compounds designed to target proteins that drive pathology in certain…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn